When your child changes overnight, you fight to understand why.

PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) are childhood conditions marked by an abrupt, severe onset of neuropsychiatric symptoms.

On this site, and in Charlie’s care, we describe PANS/PANDAS as a form of autoimmune encephalitis in which immune dysfunction and brain inflammation can drive dramatic changes in behavior, movement, mood, eating and function. The NIMH clinical overview explains the recognized diagnostic features.

PANS is the broader syndrome. Its abrupt symptoms may follow different infectious, inflammatory or immune triggers, and a specific trigger is not always identified.

PANDAS is the strep-associated subgroup. It describes the sudden onset or worsening of OCD or tics connected in time with a group A streptococcal infection. Every PANDAS case fits within the PANS framework, but not every PANS case is linked to strep.

The defining clue is a sudden, dramatic onset—often reaching full intensity within days—of OCD or severely restricted eating. Other abrupt symptoms can include extreme anxiety, emotional volatility, aggression, regression, tics or unusual movements, sensory changes, sleep disruption, frequent urination, handwriting changes and a sharp decline in school performance.

The pattern and speed of the change matter. Families often describe feeling as if they lost the child they knew almost overnight.

Care is individualized. It may include identifying and treating an active infection, addressing inflammation or immune dysfunction with an experienced specialist, and supporting psychiatric, behavioral, nutritional, sleep and school needs.

When strep is present, a clinician may prescribe antibiotics. Some children need anti-inflammatory or specialist-directed immune treatment, while therapy and carefully selected medications may help manage severe symptoms. Early recognition and coordinated care can matter.

Recovery is possible. Some children recover fully, particularly when triggers and inflammation are identified and treated. Others experience relapses or a longer course and require continued care.

No one can promise the outcome for an individual child, but PANS/PANDAS is not automatically a lifelong condition. Our family is fighting because we believe Charlie can recover and live a better life.

There is no single test that confirms PANS or PANDAS. Evaluation begins with the abrupt symptom history, timing of recent illness or exposure, and a complete medical, psychiatric and neurological examination.

Depending on the child’s presentation, a clinician may consider:

• A throat culture, rapid antigen test or molecular test for active group A strep.
• ASO and anti-DNase B strep antibody titers. Paired samples showing a rise over time can be more informative than one result.
• Targeted tests for Lyme disease, COVID-19, other infections, or mold-related illness or allergy when the child’s exposure history and symptoms support them.
• Inflammatory, metabolic, immune or autoimmune testing—and, when neurological warning signs are present, specialist-directed MRI, EEG, spinal-fluid or autoimmune-encephalitis studies.

Elevated strep antibodies are a common clue in PANDAS evaluations, including strong or first recognized onsets, but they are not universal. A single high ASO or anti-DNase B result shows prior immune exposure to strep; it cannot by itself date the infection or diagnose PANDAS. The PANS Consensus Conference recommendations and the AAP clinical report explain the areas of agreement and continuing debate.